Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

GLI2-mediated melanoma invasion and metastasis.

Alexaki VI, Javelaud D, Van Kempen LC, Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS, Fournier PJ, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise TA, Mauviel A.

J Natl Cancer Inst. 2010 Aug 4;102(15):1148-59. doi: 10.1093/jnci/djq257. Epub 2010 Jul 21.

2.

TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis.

Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A.

Cancer Res. 2011 Sep 1;71(17):5606-10. doi: 10.1158/0008-5472.CAN-11-1194. Epub 2011 Aug 23. Review.

3.

Bone structural components regulating sites of tumor metastasis.

Sterling JA, Guelcher SA.

Curr Osteoporos Rep. 2011 Jun;9(2):89-95. doi: 10.1007/s11914-011-0052-5. Review.

4.

MIA--a new target protein for malignant melanoma therapy.

Schmidt J, Riechers A, Bosserhoff AK.

Histol Histopathol. 2013 Apr;28(4):421-6. doi: 10.14670/HH-28.421. Epub 2012 Nov 22. Review.

PMID:
23192727
5.

UVA-Irradiation Induces Melanoma Invasion via the Enhanced Warburg Effect.

Kamenisch Y, Baban TS, Schuller W, von Thaler AK, Sinnberg T, Metzler G, Bauer J, Schittek B, Garbe C, Rocken M, Berneburg M.

J Invest Dermatol. 2016 Sep;136(9):1866-75. doi: 10.1016/j.jid.2016.02.815. Epub 2016 May 13. Review.

6.

The KISS1 metastasis suppressor: mechanistic insights and clinical utility.

Nash KT, Welch DR.

Front Biosci. 2006 Jan 1;11:647-59. Review.

7.

Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.

Kardos GR, Robertson GP.

Pigment Cell Melanoma Res. 2015 Sep;28(5):501-19. doi: 10.1111/pcmr.12391. Review.

Supplemental Content

Support Center